000163496 001__ 163496
000163496 005__ 20230915090523.0
000163496 0247_ $$2doi$$a10.3390/ph15020199
000163496 0247_ $$2pmid$$apmid:35215311
000163496 0247_ $$2pmc$$apmc:PMC8879883
000163496 037__ $$aDZNE-2022-00256
000163496 041__ $$aEnglish
000163496 082__ $$a610
000163496 1001_ $$00000-0001-5846-7058$$aScuteri, Damiana$$b0
000163496 245__ $$aDementia and COVID-19: A Case Report and Literature Review on Pain Management.
000163496 260__ $$aBasel$$bMDPI$$c2022
000163496 3367_ $$2DRIVER$$aarticle
000163496 3367_ $$2DataCite$$aOutput Types/Journal article
000163496 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1654870024_23355
000163496 3367_ $$2BibTeX$$aARTICLE
000163496 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000163496 3367_ $$00$$2EndNote$$aJournal Article
000163496 520__ $$aThe coronavirus disease 2019 (COVID-19) pandemic imposes an unprecedented lifestyle, dominated by social isolation. In this frame, the population to pay the highest price is represented by demented patients. This group faces the highest risk of mortality, in case of severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection, and they experience rapid cognitive deterioration, due to lockdown measures that prevent their disease monitoring. This complex landscape mirrors an enhancement of neuropsychiatric symptoms (NPSs), with agitation, delirium and reduced motor performances, particularly in non-communicative patients. Due to the consistent link between agitation and pain in these patients, the use of antipsychotics, increasing the risk of death during COVID-19, can be avoided or reduced through an adequate pain treatment. The most suitable pain assessment scale, also feasible for e-health implementation, is the Mobilization-Observation-Behaviour-Intensity-Dementia (MOBID-2) pain scale, currently under validation in the Italian real-world context. Here, we report the case of an 85-year-old woman suffering from mild cognitive impairment, subjected to off-label treatment with atypical antipsychotics, in the context of undertreated pain, who died during the pandemic from an extensive brain hemorrhage. This underscores the need for appropriate assessment and treatment of pain in demented patients.
000163496 536__ $$0G:(DE-HGF)POF4-351$$a351 - Brain Function (POF4-351)$$cPOF4-351$$fPOF IV$$x0
000163496 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000163496 650_7 $$2Other$$aCOVID-19
000163496 650_7 $$2Other$$aMOBID-2
000163496 650_7 $$2Other$$aNPSs
000163496 650_7 $$2Other$$adementia
000163496 650_7 $$2Other$$apain assessment
000163496 650_7 $$2Other$$atele-neurorehabilitation
000163496 7001_ $$00000-0002-9825-1347$$aContrada, Marianna$$b1
000163496 7001_ $$00000-0002-4867-1378$$aTonin, Paolo$$b2
000163496 7001_ $$00000-0001-6472-0697$$aCorasaniti, Maria Tiziana$$b3
000163496 7001_ $$0P:(DE-2719)2010732$$aNicotera, Pierluigi$$b4$$udzne
000163496 7001_ $$00000-0001-8540-6218$$aBagetta, Giacinto$$b5
000163496 773__ $$0PERI:(DE-600)2193542-7$$a10.3390/ph15020199$$gVol. 15, no. 2, p. 199 -$$n2$$p199$$tPharmaceuticals$$v15$$x1424-8247$$y2022
000163496 8564_ $$uhttps://pub.dzne.de/record/163496/files/DZNE-2022-00256.pdf$$yOpenAccess
000163496 8564_ $$uhttps://pub.dzne.de/record/163496/files/DZNE-2022-00256.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000163496 909CO $$ooai:pub.dzne.de:163496$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000163496 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2010732$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000163496 9131_ $$0G:(DE-HGF)POF4-351$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vBrain Function$$x0
000163496 9141_ $$y2022
000163496 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-06-15
000163496 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-06-15
000163496 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-06-15
000163496 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-06-15
000163496 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000163496 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-06-15
000163496 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bPHARMACEUTICALS-BASE : 2021$$d2022-11-29
000163496 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-29
000163496 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-29
000163496 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2022-01-15T12:16:46Z
000163496 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2022-01-15T12:16:46Z
000163496 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2022-01-15T12:16:46Z
000163496 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-29
000163496 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-29
000163496 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-29
000163496 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-29
000163496 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-29
000163496 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bPHARMACEUTICALS-BASE : 2021$$d2022-11-29
000163496 9201_ $$0I:(DE-2719)1013003$$kAG Bano$$lAging and neurodegeneration$$x0
000163496 9201_ $$0I:(DE-2719)1030000$$kScientific board$$lScientific board$$x1
000163496 980__ $$ajournal
000163496 980__ $$aVDB
000163496 980__ $$aUNRESTRICTED
000163496 980__ $$aI:(DE-2719)1013003
000163496 980__ $$aI:(DE-2719)1030000
000163496 9801_ $$aFullTexts